News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
News Pfizer's Ibrance available across UK after thumbs up in Scot... Around 800 women have received the drug for free.
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
Views & Analysis Real-world data – optimising your strategy for market access... The points to consider in preparing an effective data strategy.
Views & Analysis Accessing biosimilars: untapped potential in EU and US Though they can reduce the costs of health care, biosimilars still face challenges to access.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
